Non-small cell lung cancer
Conditions
Interventions
Ciprofol Group:Induction: 0.4 - 0.5 mg/kg, administered slowly
Maintenance: Initial infusion rate 1.0 mg/kg/h. Adjust according to BIS value (target 40 - 60) in real time, and make adjustments every 5 minutes.
Propofol Group:Induction: 1.5 - 2 mg/kg
Maintenance: TCI mode (Marsh or Schnider), target concentration 2.5 - 4 ug/ml, the adjustment target is also BIS 40 - 60.
Sponsors
Guangdong Second Provincial General Hospital (Guangdong Provincial Emergency Hospital)
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1.Patients scheduled to undergo video-assisted thoracoscopic radical lung cancer surgery (lobectomy or segmentectomy; 2.Age range: 18 - 75 years old. Gender: No restrictions. 3.American Society of Anesthesiologists (ASA) classification grades I to II; 4.Body Mass Index (BMI) ranging from 18.5 to 28.0 kg/m^2; 5.The preoperative pathological diagnosis predicted to be primary non-small cell lung cancer (NSCLC); 6.Voluntarily participate in this study and sign the informed consent form;
Exclusion criteria
Exclusion criteria: 1.Those who had received chemotherapy, radiotherapy or immunotherapy before the surgery; 2.Those with severe immune system disorders (such as autoimmune diseases, primary immunodeficiency diseases) or those who have been taking immunosuppressants/synthetic corticosteroids for a long time (more than 3 months); 3.Combined with severe liver and kidney dysfunction (Child-Pugh grade C or eGFR < 30 ml/min/1.73m^2); 4.For those who are allergic to fat emulsion, ketamine or propofol; 5.Pregnant or lactating women; 6.Participants who also took part in other clinical studies; 7.Other circumstances that the researchers considered unsuitable for inclusion in the study;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| (SRC); | — |
Secondary
| Measure | Time frame |
|---|---|
| Postoperative recovery quality;PD-1 positive rate (exhaustion marker);Physical endurance;(OCR);CD107a positive rate (degranulation function);(ECAR);NKG2D positivity rate (activation marker);Laboratory safety indicators;Adverse events; | — |
Countries
China
Contacts
Public ContactZhang hui
Guangdong Second Provincial General Hospital (Guangdong Provincial Emergency Hospital)
Outcome results
None listed